21356 - Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Disease Types: Lymphomas,&nbs

Available at: {clinical_trial_location backspace="7"}21356 - Ph2 Sub Mosunetuzumab B-cell malig, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}